FDA Approves Novel Treatment for Hairy Cell Leukemia

FRIDAY, Sept. 14, 2018 -- Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news